S&P 500   4,602.29 (+0.36%)
DOW   36,232.94 (+0.32%)
QQQ   392.03 (+0.41%)
AAPL   195.59 (+0.68%)
MSFT   373.73 (+0.75%)
META   331.96 (+1.64%)
GOOGL   134.80 (-1.56%)
AMZN   147.57 (+0.47%)
TSLA   244.16 (+0.63%)
NVDA   475.75 (+2.10%)
NIO   7.39 (-1.34%)
BABA   72.28 (-0.07%)
AMD   128.99 (+0.48%)
T   16.81 (-1.64%)
F   11.03 (+1.94%)
MU   75.16 (+2.05%)
CGC   0.78 (+8.08%)
GE   120.38 (+0.75%)
DIS   92.75 (+0.43%)
AMC   6.91 (+1.32%)
PFE   28.80 (+0.59%)
PYPL   58.91 (+0.74%)
XOM   99.39 (+0.99%)
S&P 500   4,602.29 (+0.36%)
DOW   36,232.94 (+0.32%)
QQQ   392.03 (+0.41%)
AAPL   195.59 (+0.68%)
MSFT   373.73 (+0.75%)
META   331.96 (+1.64%)
GOOGL   134.80 (-1.56%)
AMZN   147.57 (+0.47%)
TSLA   244.16 (+0.63%)
NVDA   475.75 (+2.10%)
NIO   7.39 (-1.34%)
BABA   72.28 (-0.07%)
AMD   128.99 (+0.48%)
T   16.81 (-1.64%)
F   11.03 (+1.94%)
MU   75.16 (+2.05%)
CGC   0.78 (+8.08%)
GE   120.38 (+0.75%)
DIS   92.75 (+0.43%)
AMC   6.91 (+1.32%)
PFE   28.80 (+0.59%)
PYPL   58.91 (+0.74%)
XOM   99.39 (+0.99%)
S&P 500   4,602.29 (+0.36%)
DOW   36,232.94 (+0.32%)
QQQ   392.03 (+0.41%)
AAPL   195.59 (+0.68%)
MSFT   373.73 (+0.75%)
META   331.96 (+1.64%)
GOOGL   134.80 (-1.56%)
AMZN   147.57 (+0.47%)
TSLA   244.16 (+0.63%)
NVDA   475.75 (+2.10%)
NIO   7.39 (-1.34%)
BABA   72.28 (-0.07%)
AMD   128.99 (+0.48%)
T   16.81 (-1.64%)
F   11.03 (+1.94%)
MU   75.16 (+2.05%)
CGC   0.78 (+8.08%)
GE   120.38 (+0.75%)
DIS   92.75 (+0.43%)
AMC   6.91 (+1.32%)
PFE   28.80 (+0.59%)
PYPL   58.91 (+0.74%)
XOM   99.39 (+0.99%)
S&P 500   4,602.29 (+0.36%)
DOW   36,232.94 (+0.32%)
QQQ   392.03 (+0.41%)
AAPL   195.59 (+0.68%)
MSFT   373.73 (+0.75%)
META   331.96 (+1.64%)
GOOGL   134.80 (-1.56%)
AMZN   147.57 (+0.47%)
TSLA   244.16 (+0.63%)
NVDA   475.75 (+2.10%)
NIO   7.39 (-1.34%)
BABA   72.28 (-0.07%)
AMD   128.99 (+0.48%)
T   16.81 (-1.64%)
F   11.03 (+1.94%)
MU   75.16 (+2.05%)
CGC   0.78 (+8.08%)
GE   120.38 (+0.75%)
DIS   92.75 (+0.43%)
AMC   6.91 (+1.32%)
PFE   28.80 (+0.59%)
PYPL   58.91 (+0.74%)
XOM   99.39 (+0.99%)

Axonics Stock Price, News & Analysis (NASDAQ:AXNX)

$57.23
-0.65 (-1.12%)
(As of 02:16 PM ET)
Compare
Today's Range
$57.09
$58.31
50-Day Range
$49.38
$59.14
52-Week Range
$47.59
$68.93
Volume
239,830 shs
Average Volume
632,416 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.60

Axonics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.7% Upside
$71.60 Price Target
Short Interest
Healthy
4.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.85mentions of Axonics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$436,477 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

90th out of 960 stocks

Surgical & Medical Instruments Industry

14th out of 74 stocks


AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?
Axonics (NASDAQ:AXNX) Trading Up 3.5%
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Axonics, Inc. (NASDAQ:AXNX) Short Interest Down 22.0% in November
Axonics to Participate in November Investor Conferences
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Axonics: Q3 Earnings Snapshot
Axonics Reports Third Quarter 2023 Financial Results
Axonics Announces CFO Retirement and Appoints Successor
Axonics: Rapid Growth But Waiting For Profitability
Analyst Ratings for Axonics
Why Shares of Axonics Rose Friday
Axonics: Q2 Earnings Snapshot
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$71.60
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+23.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-59,700,000.00
Pretax Margin
-4.10%

Debt

Sales & Book Value

Annual Sales
$273.70 million
Book Value
$11.51 per share

Miscellaneous

Free Float
49,725,000
Market Cap
$2.94 billion
Optionable
Not Optionable
Beta
0.48
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

10 brokerages have issued 1 year price targets for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2023?

Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX shares have decreased by 8.1% and is now trading at $57.44.
View the best growth stocks for 2023 here
.

Are investors shorting Axonics?

Axonics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, a decline of 22.0% from the October 31st total of 2,770,000 shares. Based on an average trading volume of 557,600 shares, the short-interest ratio is currently 3.9 days.
View Axonics' Short Interest
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Monday, October, 30th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.13. The business earned $93.10 million during the quarter, compared to analysts' expectations of $89.60 million. Axonics had a negative trailing twelve-month return on equity of 2.04% and a negative net margin of 3.50%. The business's revenue for the quarter was up 32.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.00%), Bamco Inc. NY (3.55%), Invesco Ltd. (3.23%), Loomis Sayles & Co. L P (2.47%), Mackenzie Financial Corp (2.46%) and Artisan Partners Limited Partnership (1.26%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -